Abstract: ［Abstract］〓Objective〖HTSS〗〓To investigate the clinical efficacy of telmisartan combined with finasteride in treatment of hypertension patients with benign prostatic hyperplasia and on the level of blood pressure, the International Prostate Symptom Score(IPSS), maximum urinary flow rate(Qmax), total prostate volume and residual urine volume.
〖HTH〗〖WTHZ〗Methods〖HTSS〗〓The 108 patients with hypertension and benign prostatic hyperplasia were randomly divided into group A, B and C with 36 cases in each group. Group A was given telmisartan treatment, group B was treated with finasteride, and group C was given telmisartan combined finasteride treatment. After 1 years of followup, the treatment effect of the 3 groups was compared and the blood pressure, IPSS, Qmax, the total volume of the prostate and the residual urine volume were observed.
〖HTH〗〖WTHZ〗Results〖HTSS〗〓The levels of SBP and DBP in three groups after treatment were significantly lower than those before treatment(P＜005). There was no significant difference in SBP and DBP levels, blood pressure lowering effect and total effective rate between the three groups(P＞005). The volume of prostate in group B and C was smaller than that in group A, and the volume of prostate in group C was significantly less than that in group B(P＜005). There was no significant difference in the effective rates of three groups of prostatic hyperplasia(P＞005). The IPSS and residual urine volume of the three groups after treatment were significantly lower than that before treatment, Qmax was significantly higher than that before treatment. IPSS and residual urine volume in group B and C was significantly lower than the group A, Qmax higher than the group A, IPSS and residual urine volume in group C was significantly lower than that of group B, and Qmax was higher than that of group B(P＜005). There was no significant difference in the incidence of adverse reactions among the three groups(P＞005).
〖HTH〗〖WTHZ〗Conclusion〖HTSS〗〓Telmisartan combined with finasteride treatment of hypertension associated with benign prostatic hyperplasia are better, which can improve the IPSS, increase Qmax, reduce residual urine output, and less adverse reactions.

Key words: hypertension； prostatic hyperplasia； telmisartan, finasteride